Robin Park, MD
Robin Park, MD
Specialty: Hematology/Oncology
Program: Head and Neck Oncology
Language(s): English
-
Overview
Cancer Focus:
Adrenal Cancer, Head and Neck Cancer, Oral Cavity or Throat Cancer, Throat Cancer, Thyroid CancerDr. Park received his MD degree from Korea University, Seoul, South Korea. He completed an Internal Medicine Residency at MetroWest Medical Center/Tufts University School of Medicine, Framingham, Massachusetts, followed by a Hematology and Medical Oncology Fellowship at Moffitt Cancer Center/University of South Florida Morsani College of Medicine.
Dr. Park’s clinical interests are in head and neck and endocrine cancers. His research interests are in the development of novel therapies with a focus on early phase drug development.
-
Participating Trials
Clinical Trial 23645
A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: XB628 ()
Status: OpenClinical Trial 23647
A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Condition: Head & Neck
Intervention: PYX-201 (); Pembrolizumab (Keytruda)
Status: OpenIf you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775. -
Publications
- Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2026 Feb.32(3):501-515. Pubmedid: 41117857. Pmcid: PMC12667737.
- Park R, Rind F, Kristoff T, Li J, Schell M, Slebos RJC, Thatikonda S, Chaudhary R, Biernacki MI, Meshkovska Y, Kaldas D, Kim HS, Farinhas J, Hernandez-Prera J, Kirtane K, Hall MS, Amelio AL, Rocco JW, Bhateja P, Steuer C, Bonomi M, Saba NF, Chung CH. Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial. Am J Clin Oncol. 2025 Sep. Pubmedid: 40905435.
-
Patient Comments
20 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments